BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 12747744)

  • 1. Concordant down-regulation of proto-oncogene PML and major histocompatibility antigen HLA class I expression in high-grade prostate cancer.
    Zhang H; Melamed J; Wei P; Cox K; Frankel W; Bahnson RR; Robinson N; Pyka R; Liu Y; Zheng P
    Cancer Immun; 2003 Feb; 3():2. PubMed ID: 12747744
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concordant expression of proto-oncogene promyelocytic leukemia and major histocompatibility antigen HLA class I in human hepatocellular carcinoma.
    Xia M; Zhang JQ; Shen YQ; Xu LH; Chen AQ; Miao FQ; Xie W
    Tissue Antigens; 2007 Oct; 70(4):272-82. PubMed ID: 17767548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proto-oncogene PML enhances antigen presentation by MHC class I molecules in human lung cancer cells.
    Chang SK; Park B; Shin J; Ahn JH; Kim IH; Ahn K
    Mol Cells; 2002 Aug; 14(1):130-5. PubMed ID: 12243342
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proto-oncogene PML controls genes devoted to MHC class I antigen presentation.
    Zheng P; Guo Y; Niu Q; Levy DE; Dyck JA; Lu S; Sheiman LA; Liu Y
    Nature; 1998 Nov; 396(6709):373-6. PubMed ID: 9845074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alteration of the PML proto-oncogene in leukemic cells does not abrogate expression of MHC class I antigens.
    Larghero J; Zassadowski F; Rousselot P; Padua RA; Degos L; Chomienne C
    Leukemia; 1999 Aug; 13(8):1295-6. PubMed ID: 10450763
    [No Abstract]   [Full Text] [Related]  

  • 6. Promyelocytic leukemia (PML) nuclear bodies are disorganized in colorectal tumors with total loss of major histocompatibility complex class I expression and LMP7 downregulation.
    Cabrera CM; Jiménez P; Concha A; Garrido F; Ruiz-Cabello F
    Tissue Antigens; 2004 May; 63(5):446-52. PubMed ID: 15104675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The PML gene is not involved in the regulation of MHC class I expression in human cell lines.
    Bruno S; Ghiotto F; Fais F; Fagioli M; Luzi L; Pelicci PG; Grossi CE; Ciccone E
    Blood; 2003 May; 101(9):3514-9. PubMed ID: 12506025
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Knocking down PML impairs p53 signaling transduction pathway and suppresses irradiation induced apoptosis in breast carcinoma cell MCF-7.
    Bao-Lei T; Zhu-Zhong M; Yi S; Jun-Jie Q; Yan D; Hua L; Bin L; Guo-Wei Z; Zhi-Xian S
    J Cell Biochem; 2006 Feb; 97(3):561-71. PubMed ID: 16215989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loss of the tumor suppressor PML in human cancers of multiple histologic origins.
    Gurrieri C; Capodieci P; Bernardi R; Scaglioni PP; Nafa K; Rush LJ; Verbel DA; Cordon-Cardo C; Pandolfi PP
    J Natl Cancer Inst; 2004 Feb; 96(4):269-79. PubMed ID: 14970276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lack of T-cell-mediated recognition of the fusion region of the pml/RAR-alpha hybrid protein by lymphocytes of acute promyelocytic leukemia patients.
    Dermime S; Bertazzoli C; Marchesi E; Ravagnani F; Blaser K; Corneo GM; Pogliani E; Parmiani G; Gambacorti-Passerini C
    Clin Cancer Res; 1996 Mar; 2(3):593-600. PubMed ID: 9816208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antigen-specific tumor vaccine efficacy in vivo against prostate cancer with low class I MHC requires competent class II MHC.
    Neeley YC; McDonagh KT; Overwijk WW; Restifo NP; Sanda MG
    Prostate; 2002 Nov; 53(3):183-91. PubMed ID: 12386918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Increase of BIRC5 gene expression in non-small cell lung cancer and esophageal squamous cell carcinoma does not correlate with expression of genes SMAC/DIABLO and PML encoding its inhibitors].
    Vaĭshlia NA; Zinov'eva MV; Sass AV; Kopantsev EP; Vinogradova TV; Sverdlov ED
    Mol Biol (Mosk); 2008; 42(4):652-61. PubMed ID: 18856066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PML nuclear bodies and SATB1 are associated with HLA class I expression in EBV+ Hodgkin lymphoma.
    Liu Y; van den Berg A; Veenstra R; Rutgers B; Nolte I; van Imhoff G; Visser L; Diepstra A
    PLoS One; 2013; 8(8):e72930. PubMed ID: 24009715
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TGF-β and EGF induced HLA-I downregulation is associated with epithelial-mesenchymal transition (EMT) through upregulation of snail in prostate cancer cells.
    Chen XH; Liu ZC; Zhang G; Wei W; Wang XX; Wang H; Ke HP; Zhang F; Wang HS; Cai SH; Du J
    Mol Immunol; 2015 May; 65(1):34-42. PubMed ID: 25618241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overexpression of PML induced apoptosis in bladder cancer cell by caspase dependent pathway.
    Li L; He D; He H; Wang X; Zhang L; Luo Y; Nan X
    Cancer Lett; 2006 May; 236(2):259-68. PubMed ID: 16216409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Specific binding of leukemia oncogene fusion protein peptides to HLA class I molecules.
    Bocchia M; Wentworth PA; Southwood S; Sidney J; McGraw K; Scheinberg DA; Sette A
    Blood; 1995 May; 85(10):2680-4. PubMed ID: 7742526
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate stem cell antigen is a promising candidate for immunotherapy of advanced prostate cancer.
    Dannull J; Diener PA; Prikler L; Fürstenberger G; Cerny T; Schmid U; Ackermann DK; Groettrup M
    Cancer Res; 2000 Oct; 60(19):5522-8. PubMed ID: 11034097
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The antigen processing machinery of class I human leukocyte antigens: linked patterns of gene expression in neoplastic cells.
    Giorda E; Sibilio L; Martayan A; Moretti S; Venturo I; Mottolese M; Ferrara GB; Cappellacci S; Eibenschutz L; Catricalà C; Grammatico P; Giacomini P
    Cancer Res; 2003 Jul; 63(14):4119-27. PubMed ID: 12874016
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recognition of a shared human prostate cancer-associated antigen by nonclassical MHC-restricted CD8+ T cells.
    Housseau F; Bright RK; Simonis T; Nishimura MI; Topalian SL
    J Immunol; 1999 Dec; 163(11):6330-7. PubMed ID: 10570328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Curative antitumor immune response is optimal with tumor irradiation followed by genetic induction of major histocompatibility complex class I and class II molecules and suppression of Ii protein.
    Wang Y; Xu M; Che M; Von Hofe E; Abbas A; Kallinteris NL; Lu X; Liss ZJ; Forman JD; Hillman GG
    Hum Gene Ther; 2005 Feb; 16(2):187-99. PubMed ID: 15761259
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.